Pacific Biosciences of California (PACB) Stock Price

Pacific Biosciences of California Inc is primarily active in the biotechnology industry.

The main competitors of Pacific Biosciences of California Inc in the market include Illumina Inc., Thermo Fisher Scientific Inc., and Oxford Nanopore Technologies Ltd.

Pacific Biosciences of California Inc is a leading biotechnology company headquartered in California. Established in 2004, the company focuses on developing innovative solutions for genetic research and targeted sequencing technologies. Pacific Biosciences of California Inc is known for its state-of-the-art DNA sequencing platforms, enabling an in-depth understanding of complex biological systems. With a strong commitment to advancing scientific knowledge, the company has made significant contributions to various fields, including genomics, personalized medicine, and evolutionary biology. Leveraging cutting-edge technology and a dedicated team of experts, Pacific Biosciences of California Inc continues to drive advancements in genetic research and provide valuable insights into the intricacies of life science.

Pacific Biosciences of California Inc has achieved several significant milestones. Firstly, the company pioneered and developed Single Molecule, Real-Time (SMRT) DNA sequencing technology, revolutionizing biological research and genomic analysis. Secondly, Pacific Biosciences launched its first commercial instrument, the PacBio RS II System, which enabled long-read sequencing with unmatched accuracy. Furthermore, the company introduced the Sequel System, delivering increased scalability, affordability, and more extensive applications. Pacific Biosciences partnered with various renowned research institutions, industry leaders, and government agencies to advance scientific discovery and genomics research worldwide. These accomplishments have positioned Pacific Biosciences of California Inc as a leading provider of innovative genomic solutions, empowering researchers and scientists in deciphering the complexities of biology.

Pacific Biosciences of California Inc is primarily present in the United States of America.

Pacific Biosciences of California Inc represents a commitment to advancing scientific research and innovation in the field of biological sciences. With a strong focus on genetic sequencing technology, Pacific Biosciences is driven by the mission to enable groundbreaking discoveries and provide valuable insights into the complexity of biological systems. The company's corporate philosophy revolves around delivering high-quality, accurate, and scalable sequencing solutions that empower researchers and drive advancements in areas such as personalized medicine, agriculture, and conservation. Pacific Biosciences of California Inc aligns its values with transparency, collaboration, and a dedication to pushing the boundaries of scientific understanding through state-of-the-art technology and research.

Analysts currently set an average price target of 1.00 USD for the Pacific Biosciences of California stock (median: 1.00 USD), implying -53.6 % versus the latest price. The consensus is based on 14 analyst ratings.

Pacific Biosciences of California Analyst Price Targets 2026

14 analysts currently rate the Pacific Biosciences of California stock: 9 recommend buying, 4 holding and 1 selling. For 2026, analysts expect Pacific Biosciences of California to generate revenue of 160.39 M USD and earnings per share of -0.47 USD.

Pacific Biosciences of California Analyst Price Targets 2026

Converted at the current exchange rate, the Pacific Biosciences of California share trades at 1.92 EUR (2.15 USD).

The Pacific Biosciences of California share (PACB) is listed on 4 stock exchanges, including: NASDAQ (PACB), Frankfurt (P09.F), München (P09.MU), Düsseldorf (P09.DU).

Pacific Biosciences of California Inc. is a company specializing in the development and marketing of DNA sequencing systems. The company was founded in 2004 and is headquartered in Menlo Park, California. Pacific Biosciences' business model focuses on providing DNA sequencing technologies and services to research institutions, pharmaceutical, and biotech companies. The company offers a portfolio of DNA sequencing systems and services to meet the needs of its customers. The product range primarily includes the SMRT (Single-Molecule, Real-Time) Sequencing System, which can analyze single molecules in real time. The SMRT system enables the detection of DNA methylation patterns, RNA transcript variants, fusion genes, and structural variations that cannot be detected by conventional sequencing methods. In addition, Pacific Biosciences also provides various services to support its customers with DNA sequencing. These include sequencing services, data analysis and reporting, as well as training and technical support. The company also has partnerships with other pharmaceutical and biotech companies to support the development of diagnostics and drugs. However, Pacific Biosciences' business model also faces challenges. The competition in the sequencing industry is strong, with established companies like Illumina and Thermo Fisher already holding a large market share. Additionally, the high costs of the systems and services can deter potential customers. The market for DNA sequencing systems is also closely tied to the research market, which is dependent on household budgets that can fluctuate over time. Nevertheless, Pacific Biosciences has experienced strong growth as more research institutions and pharmaceutical and biotech companies seek more advanced methods of DNA sequencing. In recent years, the company has also formed partnerships with companies like Invitae and Agilent Technologies to expand its presence in the diagnostics industry and provide customers with a more comprehensive solution. In summary, Pacific Biosciences' business model is centered around providing DNA sequencing technologies and services. The company offers a variety of products and services to meet the needs of research institutions and pharmaceutical and biotech companies. Pacific Biosciences' escalation model has firmly established it in the industry, and the company is committed to continuously improving and expanding its offerings to remain at the forefront of DNA sequencing technology.

The expected revenue of Pacific Biosciences of California is 160.39 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Pacific Biosciences of California is -141.40 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Pacific Biosciences of California is currently -4.60. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pacific Biosciences of California stock.

The price-to-sales ratio (P/S) of Pacific Biosciences of California is currently 4.06. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pacific Biosciences of California stock.

The Eulerpool Quality Score for Pacific Biosciences of California is 3/10.

The ISIN of Pacific Biosciences of California is US69404D1081. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Pacific Biosciences of California is A1C3EQ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Pacific Biosciences of California is PACB. The ticker symbol is used to trade Pacific Biosciences of California shares on the stock exchange.